spacer
home > pmps > spring 2007 > safe and sound
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Safe and Sound

The growing need for safety devices that meet both medical and pharmaceutical requirements results in innovative developments in prefilled syringes, argues Patrice Lewko at Rexam Pharma

Prefilled syringes have undergone dramatic development in the last 20 years, bringing more convenience and added safety. However, with the rising concern about blood borne contamination by needlesticks, the market now needs better protection for the device users. This has triggered the development of new safety systems.

Since the introduction of prefilled syringes in Europe in the 1980s, the market has enjoyed continuous growth. This trend has also been reinforced in the 1990s by the move towards injections at home by the patient.

Today, the market continues to grow by 10-20 per cent per year, depending on the geographical area, resulting in over two billion prefilled syringes sold worldwide. Their use, which was limited to heparin (Sanofi and Rhône-Poulenc) and a few other vaccines, has expanded to a whole range of new applications, such as oncology, insulin, human growth hormone, treatments for multiple sclerosis, fertility, osteoporosis, hepatitis, rheumatoid arthritis, cancer, anemia and hemophilia.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Patrice Lewko is Marketing Director for Rexam Pharma. He graduated from the Edhec Business School, France, after which he gained experience in purchasing and plastic packaging sales with Alcan (formerly Pechiney). He has been with Rexam since 1994, working in packaging solutions in both the US and Europe. Patrice is in charge of identifying the needs of the pharmaceutical industry, defining requirements and promoting the development of the corresponding products.
spacer
Patrice Lewko
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement